Crawford To Head Reorganized FDA; McClellan Moves To CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Woodcock becomes deputy commissioner for operations under an agency management reshuffling aimed at ensuring a smooth transition.
You may also be interested in...
Generic Biologics Timing Depends On FDA Commissioner, Barr Says
The products could be on the market within three years if an FDA commissioner of former chief McClellan's "disposition" is confirmed, CEO Downey says. The process could take longer if the confirmed commissioner is more "reticent to change."
Generic Biologics Timing Depends On FDA Commissioner, Barr Says
The products could be on the market within three years if an FDA commissioner of former chief McClellan's "disposition" is confirmed, CEO Downey says. The process could take longer if the confirmed commissioner is more "reticent to change."
BIO Is “Cautiously Optimistic” About Post-McClellan FDA
Senior agency officials appear committed to outgoing commissioner’s goals, BIO policy chief Werner says.